Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Федеральное государственное бюджетное научное учреждение «Научный центр психического здоровья» 2 Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет) 3 ООО «Протеинтех
Список исп. литературыСкрыть список 1. Clayton A.H., El Haddad S., Iluonakhamhe J.-P., Ponce Martinez C., Schuck A.E. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opinion on Drug Safety. 2014;13(10):1361-1374. https://doi.org/10.1517/14740338.2014.951324. 2. Clayton A.H., El Haddad S., Iluonakhamhe J.-P., Ponce Martinez C., Schuck A.E. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opinion on Drug Safety. 2014;13(10):1361-1374. https://doi.org/10.1517/14740338.2014.951324. 3. Rosenberg K.P., Bleiberg K.L. K.L., Koscis J., Gross C. A Survey of Sexual Side Effects Among Severely Mentally Ill Patients Taking Psychotropic Medications: Impact on Compliance. Journal of Sex & Marital Therapy. 2003;29(4):289-296. https://doi.org/10.1080/00926230390195524. 4. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21. 5. Петрова Е. В., Вакина Т. Н., Бурмистрова Л. А. Сексуальные дисфункции при тревожно-депрессивных расстройствах. Журнал «Лечащий врач». https://www.lvrach.ru/2014/05/15435972. Страница доступна на 01.04.2022. 6. Перетятько А.А., Маломан И.С. Сексуальные нарушения как коморбидные состояния и как осложнения терапии психотропными препаратами. https://elibrary.ru/item.asp?id=32873135. Страница доступна на 01.04.2022. 7. Образцова Е.В., Дунайцева Т.В., Мацюк Е.М., Хейгетян А.Ф. Отдельные аспекты нарушений полового поведения, ассоциированные с приемом антипсихотиков и антидепрессантов. https://elibrary.ru/item.asp?id= 37277829. Страница доступна на 01.04.2022. 8. Аведисова А.С. Побочные эффекты антидепрессантов, нарушающие сексуальные функции. Психиатрия и психофармакотерапия им ПБ Ганнушкина. 2005;7(6):322-329. 9. Montejo A., Majadas S., Rizvi S.J., Kennedy S.H. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology: Clinical and Experimental. 2011;26(8):537-542. https://doi.org/10.1002/hup.1243. 10. Montejo A.L., Calama J., Rico-Villademoros F., Montejo L., González-García N., Pérez J., Mañas J.A.A., Agüero J.A., Aldabatreku M., de La Torre Á.A., Quintanilla P.A., Lobato P.Á., Paz M.T.A., Antón J.A., González J.A., Simón J.A., Chomón A.A., Rodríguez C.B., Herrero L.B., Pérez E.B., Bonaechea B.B., González J.B., García J.C., Calvo P., Campos M., Dono C.C., Iglesias J.M.C., Del Valle J.C.D., Feliz F.D., Alfonso A.E., Izquierdo J.R.E., Barrio J.A.E., Álvarez M.E., Atienzar C.F., Cuesta J.M.F., Torre Ó.F., Vivanco E.F., Freire I., De Dios M.T.G., Mahia M.C.G., Mellado J.A.G., Nicolás M.G., Sánchez F.G., Ullán L.G., Usieto E.G., Robina F.G., Bardanca S.G., De María V.G., Izquierdo P.G., Marín E.G., Martínez R.G., Pablos E.G., Vázquez A.I.G., Zinnmerman L.G.-M., de Las Heras M.Á.H., González M.J.H., González M.H., Abella F.I., Lorenzo G.I., Iraizoz I., Ochoa J.L., Borrajo J.M.L., Ilundain J.L., Pérez M.M., Van Son J.M., Medina M.Á., Merino C.M., Eguiluz B.M., García M.J.M., Zugazabeitia B.M., Justel A.M., Morera B., Munarriz I., García J.M., León S.O., Otaño M., Yañez L.P., Pastor M., Terán J.M.P., López M.P., Nievas F.P., Portilla J.A.P., Mestre N.P., Yañez P.Q., Fernández F.R., Pérez V.R., García M.S., Iglesias S.S., de Santiago Iaz A., de Santiago Sastre J., de La Garza C.S., Granado O.S., López J.M.S., Biddle D.S., Arribas J.S., Loza A.S., Ablanedo L.S., Prieto A.T., et al. A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study. Arch Sex Behav. 2019;48(3):923-933. https://doi.org/10.1007/s10508-018-1365-6. 11. Khazaie H., Rezaie L., Rezaei Payam N., Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial. Gen Hosp Psychiatry. 2015;37(1):40-45. https://doi.org/10.1016/j.genhosppsych.2014.10.010. 12. Baldwin D.S., Chrones L., Florea I., Nielsen R., Nomikos G.G., Palo W., Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242-252. https://doi.org/10.1177/0269881116628440. 13. Jacobsen P., Zhong W., Nomikos G., Clayton A. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. The Journal of Sexual Medicine. 2019;16(10):1638-1649. https://doi.org/10.1016/j.jsxm.2019.06.018. 14. Clayton A., Kornstein S., Prakash A., Mallinckrodt C., Wohlreich M. ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder. The Journal of Sexual Medicine. 2007;4(4, Part 1):917-929. https://doi.org/10.1111/j.1743-6109.2007.00520.x. 15. Olié J.-P., Gourion D., Montagne A., Rostin M., Poirier M.-F. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Encephale. 2009;35(6):595-604. https://doi.org/10.1016/j.encep.2009.10.011. 16. Chen L.W.-H., Chen M.Y.-S., Lian Z.-P., Lin H.-S., Chien C.-C., Yin H.-L., Chu Y.-H., Chen K.-Y. Amitriptyline and Sexual Function: A Systematic Review Updated for Sexual Health Practice. Am J Mens Health. 2018;12(2):370-379. https://doi.org/10.1177/1557988317734519. 17. Francois D., Levin A.M., Kutscher E.J., Asemota B. Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management. Psychiatric Annals. 2017;47(3):154-160. https://doi.org/10.3928/ 00485713-20170201-01. 18. Higgins A., Nash M., Lynch A.M. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141-150. https://doi.org/10.2147/DHPS.S7634. 19. Keks N.A., Hope J., Culhane C. Management of antidepressant-induced sexual dysfunction. Australas Psychiatry. 2014;22(6):525-528. https://doi.org/10.1177/1039856214556323. 20. Reichenpfader U., Gartlehner G., Morgan L.C., Greenblatt A., Nussbaumer B., Hansen R.A., Van Noord M., Lux L., Gaynes B.N. Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis. Drug Saf. 2014;37(1):19-31. https://doi.org/10.1007/s40264-013-0129-4. 21. Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M.J., Metz A. Prevalence of Sexual Dysfunction Among Newer Antidepressants. J Clin Psychiatry. 2002;63(4):15499. 22. Montejo et al. Incidence of Sexual Dysfunction Associated With Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients. J Clin Psychiatry.:12. 23. McGahuey C.A., Gelenberg A.J., Laukes C.A., Moreno F.A., Delgado P.L., McKnight K.M., Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40. https://doi.org/10.1080/ 009262300278623. 24. Montejo A.L., Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther. 2008;34(3):227-239. https://doi.org/10.1080/00926230701866125. 25. Montejo-González A.L., Llorca G., Izquierdo J.A., Ledesma A., Bousoño M., Calcedo A., Carrasco J.L., Ciudad J., Daniel E., De la Gandara J., Derecho J., Franco M., Gomez M.J., Macias J.A., Martin T., Perez V., Sanchez J.M., Sanchez S., Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194. https://doi.org/10.1080/00926239708403923. 26. Moore B.E., Rothschild A.J. Treatment of antidepressant-induced sexual dysfunction. Hosp Pract (1995). 1999;34(1):89-91, 95-96. https://doi.org/ 10.3810/hp.1999.01.127. 27. Rothschild A.J. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152(10):1514-1516. https://doi.org/10.1176/ajp.152.10.1514. 28. Baldwin D.S., Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013;202:396-397. https://doi.org/10.1192/bjp.bp.112.110650. 29. Balon R., Segraves R.T. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther. 2008;34(4):353-365. https://doi.org/10.1080/00926230802096390. 30. Andersson K.-E. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011;63(4):811-859. https://doi.org/10.1124/pr.111.004515. 31. Taylor M.J., Rudkin L., Bullemor-Day P., Lubin J., Chukwujekwu C., Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;(5):CD003382. https://doi.org/10.1002/14651858.CD003382.pub3. 32. Nurnberg H.G., Hensley P.L., Heiman J.R., Croft H.A., Debattista C., Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395-404. https://doi.org/10.1001/jama.300.4.395. 33. Тевлин К.П., Брук Ю.Ф. Вопросы выбора ингибиторов ФДЭ-5: эффективность и безопасность. Экспериментальная и клиническая урология. 2013;(2):46-50. 34. Waldinger M.D. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol. 2015;130:469-489. https://doi.org/10.1016/B978-0-444-63247-0.00027-4. 35. Wheatley D.P., van Moffaert M., Timmerman L., Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59(6):306-312. 36. Gelenberg A.J., McGahuey C., Laukes C., Okayli G., Moreno F., Zentner L., Delgado P. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000;61(5):356-360. https://doi.org/10.4088/jcp.v61n0506. 37. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21. 38. Jacobsen P.L., Mahableshwarkar A.R., Palo W.A., Chen Y., Dragheim M., Clayton A.H. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367-378. https://doi.org/10.1017/ S1092852915000553. 39. Jacobsen P.L., Mahableshwarkar A.R., Chen Y., Chrones L., Clayton A.H. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med. 2015;12(10):2036-2048. https://doi.org/10. 1111/jsm.12980. 40. Jacobsen P.L., Nomikos G.G., Zhong W., Cutler A.J., Affinito J., Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr. 2020;25(1):50-63. https://doi.org/10.1017/S1092852919000750. 41. Montejo A., Majadas S., Rizvi S.J., Kennedy S.H. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol. 2011;26(8):537-542. https://doi.org/10.1002/hup.1243. 42. Kennedy S.H., Rizvi S., Fulton K., Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28(3):329-333. https://doi.org/10.1097/JCP.0b013e318172b48c. 43. Montejo A., Prieto N., Terleira A., Matias J., Alonso S., Paniagua G., Naval S., Parra D.G., Gabriel C., Mocaër E., Portoles A. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of psychopharmacology (Oxford, England). 2008;24:111-20. https://doi.org/10.1177/0269881108096507. 44. Montejo A.L., Deakin J.F.W., Gaillard R., Harmer C., Meyniel F., Jabourian A., Gabriel C., Gruget C., Klinge C., MacFayden C., Milligan H., Mullings E., Goodwin G. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol. 2015;29(10):1119-1128. https://doi.org/10.1177/0269881115599385. 45. Montgomery S.A. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995;10 Suppl 4:37-45. https://doi.org/10.1097/00004850-199512004-00006. 46. Michelson D., Kociban K., Tamura R., Morrison M.F. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res. 2002;36(3):147-152. https://doi.org/10.1016/s0022-3956(01)00060-7. 47. Ozmenler N.K., Karlidere T., Bozkurt A., Yetkin S., Doruk A., Sutcigil L., Cansever A., Uzun O., Ozgen F., Ozsahin A. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2008;23(4):321-326. https://doi.org/ 10.1002/hup.929. 48. Atmaca M., Korkmaz S., Topuz M., Mermi O. Mirtazapine Augmentation for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: A Retropective Investigation. Psychiatry Investig. 2011;8(1):55-57. https://doi.org/10.4306/pi.2011.8.1.55. 49. Stryjer R., Spivak B., Strous R.D., Shiloh R., Harary E., Polak L., Birgen M., Kotler M., Weizman A. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009;32(2):82-84. https://doi.org/10.1097/WNF. 0B013E31816D1CDC. 50. Landén M., Eriksson E., Agren H., Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-271. https://doi.org/ 10.1097/00004714-199906000-00012. 51. Modabbernia A., Sohrabi H., Nasehi A.-A., Raisi F., Saroukhani S., Jamshidi A., Tabrizi M., Ashrafi M., Akhondzadeh S. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology (Berl). 2012;223(4):381-388. https://doi.org/10.1007/s00213-012-2729-6. 52. Lorenz T., Meston C. Exercise improves sexual function in women taking antidepressants: Results from a randomized crossover trial. Depression and Anxiety. 2014;31. https://doi.org/10.1002/da.22208. 53. Micheli L., Ceccarelli M., D’Andrea G., Tirone F. Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise. Brain Research Bulletin. 2018;143:181-193. https://doi.org/ 10.1016/j.brainresbull.2018.09.002.